New treatment for ovarian cancer! Olapari and Bevalazumab combination therapy approved in the United States for HRD-positive advanced ovarian cancer patients first-line maintenance treatment

May 11, 2020, AstraZeneca and Mercado jointly announced that the jointly developed PARP inhibitor Liptro® (Name Lynparza, generic name: Olapari) has been approved by the U.S Food and Drug Administration (FDA) to extend adaptation the disease, combined with bevacizumab, is a first-line maintenance therapy for the treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who achieve full or partial remission after first-line platinum-based chemotherapy Tumors in such patients are positive for homologous recombinant defects (HRD-plus) with harmful or suspected harmful BRCA gene mutations and/or genomic instability The company will select treatment patients based on accompanying diagnostic tests approved by the FDA FDA approval is based on biomarker subgroup analysis results from Phase III PAOLA-1 clinical trials The analysis showed that the risk of progression or death in patients with the Olapari combined bevalbezumab group was reduced by 67% (risk ratio: 0.33) compared to the control group (single bevalmono-maintained therapy) In HRD-positive patients with advanced ovarian cancer, the median progression survival (PFS) of patients can be extended to 37.2 months with the combination of Olapari and Bevalzumab With the treatment of bevalbea monomonomono, the median non-progressive survival of patients was 17.7 months about one-half of HRD-positive tumors in patients with advanced ovarian cancer For patients with advanced ovarian cancer, the main purpose of first-line treatment is to delay the progression of the disease as much as possible in order to achieve long-term relief "Ovarian cancer is a deadly disease," said Iabelle Ray-Coquard, lead researcher in the PAOLA-1 clinical trial and a medical oncologist at the L?on B?rard Center and president of the GINECO Group HRD-positive patients benefit very well in PAOLA-1 clinical trials The combination of Olapari and Bevalzumab provides a new standard treatment for HRD-positive patients with advanced ovarian cancer, and I look forward to it being translated into clinical practice "This approval is another milestone in The Treatment of Ovarian Cancer by AstraZeneca," said Dave Fredrickon, AstraZeneca's global executive vice president and head of oncology The median progression of patients has a duration of more than three years, which is expected to help more patients delay the recurrence of this refractory disease The results further demonstrate that HRD positive is a unique branch of ovarian cancer, and HRD testing is now a key component of diagnosis and personalized treatment in patients with advanced ovarian cancer "By deepening understanding of biomarkers and PARP inhibition, dr Roy Bayne, senior vice president and head of global clinical development at the 's Mercadon Research Laboratory, has fundamentally changed the way doctors treat this aggressive cancer." The approval is based on the results of the PAOLA-1 trial, which highlights the importance of HRD testing for diagnosis and helps us identify patients who are expected to benefit from olapari and bevalzumab monoantigen scoping therapy The full results of the phase III clinical trial PAOLA-1 were published in the New England Journal of Medicine based on the results of the PAOLA-1 trial, the European Union, Japan and other countries are currently conducting an indication scant review of Olapari As part of a large rife development program, the company is using Olapari monotherapy and combination therapy in trials of multiple tumor types, including in the Olymp III Phase III trial for potential complementary treatments for patients with BRCA mutations and high-risk HER2-negative primary breast cancer the indications mentioned in this article are still in the research and development stage and have not yet been approved in China AstraZeneca does not recommend any unapproved drug use methods